Under the agreement, the prices of Ozempic and Wegovy from Novo Nordisk will decline from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

Executives at Voya said they are happy Voya pushed up stop-loss prices and imposed tough underwriting standards this year.

Executives at Aflac are hoping that strong dental insurance sales will buoy sales of cancer insurance, hospital indemnity insurance and other worksite benefits products.

“The announcement that we made a few days ago was not really financially driven, and it’s not even really AI-driven, not right now at least,” said Amazon's CEO Andy Jassy in a Q3 earnings call.